ODINSIGNAL JOURNAL · NEWS & EVENTS
FDA PDUFA decision on Corcept’s relacorilant for Cushing’s syndrome due Dec 17 2026
Corcept Therapeutics’ relacorilant for Cushing’s syndrome has a PDUFA target date of Dec 17 2026. The FDA decision will be announced by then.
Corcept Therapeutics has resubmitted its New Drug Application for relacorilant, an oral agent aimed at treating hypercortisolism caused by Cushing’s syndrome. The FDA’s Prescription Drug User Fee Act (PDUFA) target date for a decision is December 17, 2026 see source.
The deadline marks the latest point at which the agency must complete its review. If approved, relacorilant would become the first oral therapy specifically targeting this rare endocrine disorder.
Stakeholders will be watching the outcome closely, as the decision will shape treatment options for patients and may influence future development pathways for cortisol‑targeting drugs.
Follow the event on OdinSignal for real‑time updates as the date approaches.
FOLLOW THE EVENT
What happens next?
Explore the event, review its rules, and share your prediction on OdinSignal.
Explore the prediction market →Virtual credits only. No cash value.More from the Journal
Summit Therapeutics’ ivonescimab receives FDA PDUFA goal date of Nov 14 2026
Summit Therapeutics’ ivonescimab (HARMONi) BLA has a FDA PDUFA goal action date of November 14 2026 for non‑small cell lung cancer.
Read article →OPEC to Hold 42nd Ministerial Meeting on 29 November 2026
OPEC and non‑OPEC participating countries will convene on 29 Nov 2026 for the 42nd Ministerial Meeting, reaffirming the current crude‑oil production framework.
Read article →U2’s 16th Studio Album ‘Carnaval De Luz’ Set for November 13, 2026 Release
Island Records confirms U2’s new album ‘Carnaval De Luz’ will drop on November 13, 2026, marking their first studio album of new material in nine years.
Read article →Prediction markets express uncertainty, not established outcomes. OdinSignal uses virtual credits with no cash value.